Sonnet BioTherapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Narrative)

Commitments and Contingencies (Details Narrative) € in Millions	1 Months Ended			3 Months Ended			6 Months Ended
	Apr. 30, 2022 USD ($)	Mar. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Mar. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Mar. 31, 2023 USD ($)	Mar. 31, 2024 USD ($)	Mar. 31, 2023 USD ($)	Mar. 31, 2024 EUR (€)	Apr. 30, 2023 USD ($)	Oct. 31, 2021 USD ($)	Jan. 31, 2019 USD ($)	Jul. 31, 2012 USD ($)
Loss Contingencies [Line Items]
Payment to acquire in process research and development								$ 261,250
Discovery Collaboration Agreements [Member] \| XOMA [Member]
Loss Contingencies [Line Items]
Milestone payments													$ 3,800,000
Discovery Collaboration Agreements [Member] \| XOMA [Member] \| In Process Research and Development [Member]
Loss Contingencies [Line Items]
License fee	$ 500,000			$ 0		$ 0	$ 0	0
Cellca Agreement [Member]
Loss Contingencies [Line Items]
Description of milestone payments							The Company is obligated to make milestone payments to Cellca totaling up to $0.7 million upon the achievement of certain development and approval milestones if the Buy-Out Option is not exercised.
Cellca Agreement [Member] \| Maximum [Member]
Loss Contingencies [Line Items]
Milestone payments												$ 700,000
The Cellca Agreement [Member]
Loss Contingencies [Line Items]
Milestone payments				600,000			$ 600,000
The Cellca Agreement [Member] \| Maximum [Member]
Loss Contingencies [Line Items]
Payment for annual license fee obligation				600,000			600,000
The Cellca Agreement [Member] \| Minimum [Member]
Loss Contingencies [Line Items]
Payment for annual license fee obligation				100,000			100,000
The Cellca Agreement [Member] \| In Process Research and Development [Member]
Loss Contingencies [Line Items]
License fees	$ 100,000			0	$ 0	0	0
The Brink Agreement [Member]
Loss Contingencies [Line Items]
Payment of annual license fee										$ 12,000
Commercial product license fee payment obligation				100,000			100,000
The Brink Agreement [Member] \| In Process Research and Development [Member]
Loss Contingencies [Line Items]
License fee				0		12,000	12,000	12,000
Development license fee payments											$ 100,000
InvivoGen Agreement [Member]
Loss Contingencies [Line Items]
Payment for annual license fee obligation				100,000			100,000		€ 0.1
License fees				0		0	0	0
ProteoNic Agreement [Member]
Loss Contingencies [Line Items]
License fees				0			0
ProteoNic Agreement [Member] \| In Process Research and Development [Member]
Loss Contingencies [Line Items]
License fees		$ 24,600
Navigo Agreement [Member] \| Navigo Proteins GmbH [Member] \| Technology Service [Member]
Loss Contingencies [Line Items]
Milestone payments			$ 1,000,000.0
Payment to acquire in process research and development			$ 100,000
Navigo Agreement [Member] \| Navigo Proteins GmbH [Member] \| Technology Service [Member] \| Research and Development Expense [Member]
Loss Contingencies [Line Items]
Milestone payments				0		0	0	0
License fees				$ 0		$ 0	$ 0	$ 100,000